<?xml version='1.0' encoding='utf-8'?>
<document id="23922054"><sentence text="Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors." /><sentence text="Onartuzumab is a unique, humanized, monovalent (one-armed) monoclonal antibody (mAb) against the MET receptor" /><sentence text=" The intravenous (IV) pharmacokinetics (PK) of onartuzumab were investigated in a phase I study and a phase II study in recurrent non-small cell lung cancer (NSCLC) patients" /><sentence text=" The potential for drug-drug interaction (DDI) was assessed during co-administration of IV onartuzumab with oral erlotinib, by measuring the PK of both drugs"><entity charOffset="113-122" id="DDI-PubMed.23922054.s4.e0" text="erlotinib" /></sentence><sentence text=" The concentration-time profiles of onartuzumab were adequately described using a two-compartment model with linear clearance (CL) at doses between 4 and 30 mg/kg" /><sentence text=" The estimates for CL, central compartment volume (V1 ), and median terminal half-life were 0" /><sentence text="439 L/day, 2" /><sentence text="77 L, and 13" /><sentence text="4 days, respectively" /><sentence text=" Statistically significant covariates included creatinine clearance (CrCL) on clearance, weight and gender on V1 , and weight on peripheral compartment volume (V2 ), but the clinical relevance of these covariates needs to be further evaluated"><entity charOffset="47-57" id="DDI-PubMed.23922054.s10.e0" text="creatinine" /></sentence><sentence text=" The current analysis did not indicate obvious DDI between onartuzumab and erlotinib"><entity charOffset="75-84" id="DDI-PubMed.23922054.s11.e0" text="erlotinib" /></sentence><sentence text=" MET diagnostic status did not impact the exposure of either agent" /><sentence text=" Despite the slightly faster clearance compared with typical bivalent mAbs, the PK of onartuzumab support dosing regimens of 15 mg/kg every 3 weeks or doses equivalent to achieve the target minimum tumoristatic concentration in patients" /><sentence text=" " /></document>